

Notice: This is a translation of a notice in Japanese and is made solely for the convenience of foreign shareholders. In the case of any discrepancy between the translation and the Japanese original, the latter shall prevail.

[Translation]

May 12, 2022

To: Shareholders

Company name            Renascience Inc.  
Name of Representative: Koji Naito, President & CEO  
(Securities Code: 4889 Tokyo Stock Exchange Growth)  
Inquiries to: Kazuhiro Ikeda, Director, CFO

**Notice Regarding the Recording of Extraordinary  
Losses (Impairment Losses)**

The “Company” hereby announces that it has recorded the following extraordinary loss (impairment loss) for the fourth quarter of the fiscal year ending March 31, 2022 (January 1, 2022 to March 31, 2022). The following extraordinary loss (impairment loss) was recorded.

Particulars

1. Extraordinary loss (Impairment loss)

In the fourth quarter of the fiscal year ending March 31, 2022 (January 1, 2022 to March 31, 2022), the Company recognized an impairment loss of ¥11,318 thousand on the Company's patents related to RS8001 schizophrenia in accordance with the "Accounting Standard for Impairment of Fixed Assets".

2. Impact on business performance

This matter is reflected in the "Financial Results for the Fiscal Year Ended March 31, 2022 [Japanese GAAP] (Non-consolidated)" released today.

End